Upper Tract Tumors

Current staging for Upper Tract Urothelial Carcinoma (UTUC) fails to capture host biological heterogeneity. We aimed to develop and validate a machine - learning based prognostic signature integrating systemic immune - inflammatory and nutritional markers to enhance UTUC risk stratification.

Minimally invasive radical nephroureterectomy (RNU) has been increasingly adopted for upper tract urothelial carcinoma (UTUC); however, direct comparisons between laparoscopic and robot-assisted approaches remain limited.

Upper tract urothelial carcinoma (UTUC) accounts for approximately 5-10% of diagnosed urothelial carcinoma (UC). Due to advanced initial presentation or aggressive progression of UTUC, the majority of patients will need systematic treatment in the neo-adjuvant or adjuvant setting.

Upper tract urothelial carcinoma (UTUC) presents distinct diagnostic and therapeutic challenges because of its rarity, anatomic constraints, frequent understaging at biopsy, and risk of systemic recurrence after radical nephroureterectomy.

Upper tract urothelial carcinoma (UTUC) is a rare subtype of urothelial malignancy associated with poor prognosis, particularly in advanced stages. Sex determining region-Y-related high mobility group box 2 (SOX2), a key transcription factor involved in the maintenance of cellular stemness, has been identified as a potential biomarker in multiple cancer types; however, its prognostic significance in UTUC remains unclear.

Endoscopic management offers renal-sparing approaches for upper tract urothelial carcinoma (UTUC). We sought to characterize the impact of endoscopically managing UTUC on kidney function and identify predictors of renal function decline.

Seeding and implantation are major mechanisms of intravesical recurrence (IVR) following the radical nephroureterectomy (RNU) of upper tract urothelial carcinoma (UTUC). We herein hypothesized that bladder biopsies (BB) may increase the IVR risk by promoting implantation in injured bladder mucosa.

Endoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk.

Endoscopic kidney-sparing management is increasingly being used for upper tract urothelial carcinoma; however, its use in high-grade diseases remains challenging.

An 82-year-old man with a solitary left kidney underwent transurethral lithotripsy for left renal and ureteral stones 25 years after right nephroureterectomy for ureteral carcinoma.

Liquid-based biomarkers (LBBs), derived from urine and blood, are gaining attention in the management of upper tract urothelial carcinoma (UTUC) as potential tools to overcome limitations of current diagnostic and risk stratification pathways.